Epigenetic silencing of the imprinted geneZAC by DNA methylation is an early event in the progression of human ovarian cancer

2005 ◽  
Vol 115 (5) ◽  
pp. 690-700 ◽  
Author(s):  
Tetsuya Kamikihara ◽  
Takahiro Arima ◽  
Kiyoko Kato ◽  
Takao Matsuda ◽  
Hidenori Kato ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Dna Methylation ◽  
Epigenetic Silencing ◽  
Early Event ◽  
Human Ovarian Cancer

scholarly journals Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer

2014 ◽  
Vol 31 (5) ◽  
pp. 2139-2146 ◽  
Author(s):  
NAM HEE KIM ◽  
HYE YOUN SUNG ◽  
EUN NAM CHOI ◽  
DAHYUN LYU ◽  
HYUCK JAE CHOI ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Dna Methylation ◽  
Xenograft Model ◽  
Human Ovarian Cancer ◽  
Metastatic Phenotype ◽  
Aberrant Dna Methylation

Down-regulation of MDR1 by epigenetic alteration in human epithelial ovarian cancer cells

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16556-e16556
Author(s):  
Y. Kawakami ◽  
K. Miyamoto ◽  
K. Takehara ◽  
M. Kumagai ◽  
O. Samura ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Dna Methylation ◽  
Ovarian Cancer Cell ◽  
Methylation Status ◽  
Mdr1 Gene ◽  
Human Ovarian Cancer ◽  
Rt Pcr ◽  
Specific Pcr ◽  
Ovarian Cancers ◽  
Ovarian Cancer Cell Lines

e16556 Background: Ovarian cancer is one of the most lethal malignancies in women. Despite recent studies of many oncogenes and tumor-suppressor genes concerning about its progression, the details of ovarian cancer biology still remains to be unclear. P-glycoprotein (P-gp) encoded by the MDR1 gene is a membrane protein that can export many kinds of antineoplastic agents from cells, and overexpression of P-gp has been reported to be implicated in treatment failure in cancer. DNA methylation, a major epigenetic process, can affect every step in carcinogenesis as well as genetic alterations. The contribution of such epigenetic alteration to the expression of MDR1 remains largely unexplored in human ovarian cancer. Methods: In this study, we evaluated the DNA methylation status of the MDR1 gene by methylation-specific PCR. Then, the expression of MDR-1 mRNA and protein in primary epithelial ovarian cancer specimens were evaluated by real-time RT-PCR and immunohistochemistry using anti-mouse P-gp F4 monoclonal antibody, respectively. The correlation between these results and clinicopathological features was examined. Results: MDR1 was hypermethylated in 12 of 12 (100%) ovarian cancer cell lines, and 5 of 13 (38%) primary ovarian cancers by methylation-specific PCR analysis. MDR1 mRNA expression was subsequently found to be lost in ovarian cancer cell lines with methylation by both real-time RT-PCR and immunohistochemistry. Thus, MDR1expression was associated with the DNA methylation status of the MDR1 gene. Conclusions: In conclusion, MDR1 was frequently hypermethylated in human ovarian cancers. Our results suggest that epigenetic regulation might play a role in the expression of MDR1 and clinical treatment outcomes in human ovarian cancer. No significant financial relationships to disclose.

scholarly journals A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation

2012 ◽  
Vol 41 (3) ◽  
pp. 1139-1147 ◽  
Author(s):  
KANG-MI KIM ◽  
MYUNG-HA SONG ◽  
MIN-JU KIM ◽  
SAYEEMA DAUDI ◽  
ANTHONY MILIOTTO ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Dna Methylation ◽  
Human Ovarian Cancer ◽  
Cancer Testis Antigen ◽  
Cancer Testis

Regulation of apoptosis in human ovarian cancer

1998 ◽  
Vol 5 (1) ◽  
pp. 46A-46A
Author(s):  
B TSANG ◽  
J LI ◽  
Q FENG ◽  
P LISTON ◽  
J KIM ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Human Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document